Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here?

Kathlene Tracy a,b,*, Leah Wachtel a, Teri Friedman c,d

a Laboratory of Psychosocial Processes in Addiction, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, 1399 Park Avenue, New York, NY 10029, United States
b Psychosocial Division, Addiction Institute of Mount Sinai (AIMS), and Friedman Brain Institute (FBI), 1470 Madison Avenue, New York, NY 10029, United States
c Opioid Treatment Program, Mount Sinai Beth Israel, 103 E. 125th Street, 3rd floor, New York, NY 10025, United States
d Board of Directors, New York State Coalition of Medication Assisted Treatment Providers and Advocates (COMPA), 121 West 36th Street, #201, New York, NY 10018, United States

ARTICLE INFO

Keywords:
COVID-19
Opioid use disorder
Addiction services
Medication for opioid use disorders
Methadone

ABSTRACT

Medication for opioid use disorder (MOUD) services is key to addressing the opioid crisis and COVID-19 has significantly impacted MOUD delivery. The need for social distancing and self-quarantining requires individuals to maintain personal physical space and limits face-to-face interactions, which are required for methadone dispensing and other regulated treatment activities. Mount Sinai Beth Israel, which has one of the largest opioid treatment service (OTP) delivery systems within the United States and included 10 OTP methadone clinics that responded rapidly by implementing procedures to address the additional challenges during the COVID-19 pandemic. This article discusses four key procedural areas: 1) verified identity in-person pick-up doses, 2) drug urine toxicology screens, 3) treatment interactions, and 4) discharges, which can inform future OTP operational procedures by encouraging out-of-the-box thinking in this new age.

The opioid crisis is a nationwide public health emergency (Centers for Disease Control, 2020; Hargan, 2018). Essential medication for opioid use disorder (MOUD) faces significant impacts from COVID-19 (Bell & Strang, 2020; Connelly, 2015; Sun et al., 2020). Mount Sinai Beth Israel (MSBI) has one of the largest opioid use services within the country, including 10 opioid treatment programs (OTPs) that responded swiftly to COVID-19. Located within the pandemic epicenter, New York City (NYC), we knew the critical importance of promptly addressing the resulting challenges in delivering opioid treatment and impact to regulated operational procedures (Substance Abuse and Mental Health Service Administration, 2020; The Joint Commission, 2020).

Methadone is a controlled substance that physicians administer to individuals with opioid use disorders (OUDs); it requires a regimented treatment trajectory with regulations outlining training for prescribers, storage, dissemination, and continued evaluation (Atterman et al., 2018). Challenges to methadone dispensing arose due to the COVID-19 pandemic, stemming from the increased need for social distancing and isolation (Alexander & Stoller, 2020), which required personal space and limits on face-to-face interactions, necessary components of methadone dispensing and treatment. Reports indicate that COVID-19 has reduced onsite medication visits close to half, with patients continuing treatment having accommodations for take-home medication and delivery services (Peavey et al., 2020).

Within our addiction service delivery system’s 10 OTP methadone clinics in 2020, we rapidly implemented procedures to address four key areas that COVID-19 impacted.

1) OTPs frequently use verified identity in-person pick-up doses to avoid large distribution of a controlled substance so as to reduce overdose risks. Pre-COVID-19, patients picked up medication 6 days per week if new to treatment or actively using substances. During COVID-19, we implemented a rapid reduction in pick-up dose requirements, including 14-day and 28-day take home dose coverage for those patients not new to treatment or using who did not reach stability yet; transition varied depending on the individual patient’s characteristics. Medication visits dropped 44% from the same time the previous year, primarily due to these changes and shifting resources. Most patients had their pick-up schedule frequency changed...
obtain additional input on status through direct observation (e.g., smell of alcohol on breath, marijuana odor). OTPs provided support groups for personal devices, future guidance should consider public use devices stationed at places within the community where patients reside (e.g., homeless shelters, safe havens, residential facilities).

4) The OTPs met discharges with more leniency amid the COVID-19 pandemic, as local and state government reduced and limited mobility. The OTPs made every effort to retain patients with no forced administrative discharges during this time. However, given that we are a large system, if patients posed a safety risk to others or treatment was contraindicated, we transferred patients to other MSBI OTPs, to provide patients with an alternative environment.

As all MSBI OTPs are part of the same system, they were able to consistently roll out new procedures across all clinics with no approach variations. Starting at the end of March 2020, the team worked diligently to adjust all patients’ pick-up schedules, the process for which lasted 2 weeks. The OTPs had approximately 5400 patients at the time, with approximately 85% of patient medication schedules revised. Less than 1% of our patients received home delivery via courier services. We saw a drastic drop, 21% decrease from March to April, in medication visits and subsequent drop in patient engagement that began to increase again in July. Interestingly, the percentage of positive toxicology results on site medication dispensing as well as a decrease in ancillary services such as counseling, Medicaid and OASAS established a bundled rate that provided payment for take-home medications. Our facility is currently working with our billing vendor to accommodate this change and determine its sustainability.

Overall, the patient population tends to be disenfranchised and socially isolated, leading some clients to continue daily pick-ups, stating that clinic visits, including group/peer counseling, are a main source of their social interaction.

Pre-COVID-19 payment rates were based on fee-for-service, in which each type of clinical service was associated with a different amount, excluding at-home medication administrations. Given that the OTPs reduced on-site medication dispensing as well as a decrease in ancillary services such as counseling, Medicaid and OASAS established a bundled rate that provided payment for take-home medications. Our facility is currently working with our billing vendor to accommodate this change and determine its sustainability.

Individuals with OUD are at risk during the COVID-19 pandemic due to an increase in stress, feelings of isolation, and concerns such as economic insecurity and job loss, compounded with the health concerns in the population (Clay, 2020; Volkow, 2020). These concerns are particularly harmful to individuals with OUDs as they are shown to influence use, relapse, and increased vulnerability to contracting the COVID-19 virus (Clay, 2020; Volkow, 2020). While individuals with OUD have increased service needs, the strict regulations and clinician involvement created a new flexibility and adaptation for MSBI OTPs (Alexander & Stoller, 2020; Peavey et al., 2020). We have reached a new era, one requiring out-of-the-box thinking to ensure the safety of those we treat, our providers, and surrounding community. We must continue to find ways to build upon our initial adaptations and pave the way for a future vision, one that might look very different from what we once knew but that is marked by creativity and hope.

CRediT authorship contribution statement

Kathlene Tracy, Ph.D.: Conceptualization, Methodology, Writing - Original draft, Writing - Review & editing
Leah Wachtel, M.A.: Methodology, Writing - Original draft, Writing - Review & editing
Teri Friedman, M.S., C.R.C.: Methodology, Formal analysis, Writing - Review & editing, Project administration.

Declaration of competing interest

None.

Acknowledgements

We would like to acknowledge and thank the following entities as without their support this work would not have been possible: 1) Addiction Institute of Mount Sinai (AIMS), 2) Department of Psychiatry within Icahn School of Medicine at Mount Sinai, 3) Friedmann Brain Institute (FBI), 4) Mount Sinai Beth Israel, 5) NYS Office of Addiction Services and Supports (OASAS) and 6) New York City Department of Health and Mental Hygiene (NYC DOHMH). In addition, we would like to recognize our OTP patients/families and staff for their strength and resiliency during these challenging times.

References

Alexander, G. C., & Stoller, K. B. (2020). An epidemic in the midst of a pandemic: Opioid use disorder and COVID-19. Ideas and Opinions: Annals of Internal Medicine.
Attemar, J., Dormond, M., Schreiber, J., Haffajee, R., Adraksa-Christou, B., Singer, P., Haworth, S. M., Foney, D. M., & Pozuelos, S. (2018). Behavioral health workforce implementation challenges related to medication assisted treatment. Behavioral Health Workforce Research Center http://www.behavioralhealthworkforce.org/wp-content/uploads/2018/04/Y2PAO3Pz_MAT-Full-Report.pdf, (Accessed 13 June 2020).
Bell, J., & Strang, J. (2020). Medication treatment of opioid use disorder. Biological Psychiatry, 1(87), 82–88.
Centers for Disease Control and Prevention. (2020). Understanding the epidemic. http://www.cdc.gov/drugoverdose/epidemic/index.html. (Accessed 13 June 2020).
Clay, R. A. (2020, April 15). Advice for treating and preventing substance use during COVID-19. American Psychological Association. https://www.apa.org/topics/covid-19/substance-use. (Accessed 13 June 2020).

Connery, H. S. (2015). Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harvard Review of Psychiatry, 63–75.

Hargan, E. D. (2018). Determination that a public health emergency exists. https://www.phe.gov/emergency/news/healthactions/phs/Pages/opioids.aspx. (Accessed 13 June 2020).

Peavey, K. M., Darnton, J., Grekin, P., Russo, M., Banta Green, C. J., Merrill, J. O., … Tsui, J. L. (2020). Rapid implementation of service delivery changes to mitigate COVID-19 and maintain access to methadone among persons with and at high-risk for HIV in an opioid treatment program. AIDS and Behavior, 1–4.

Substance Abuse and Mental Health Service Administration (SAMHSA). (2020). MAT statutes, regulations, and guidelines. https://www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines. (Accessed 13 June 2020).

Sun, Y., Bao, Y., Kosten, T., Strang, J., Shi, J., & Lu, L. (2020). Editorial: Challenges to opioid use disorder during COVID-19. The American Journal on Addictions, 29, 174–175.

The Joint Commission. (2020). Facts about opioid treatment program accreditation. https://www.jointcommission.org/en/accreditation-and-certification/health-care-settings/behavioral-health-care/facts-about-opioid-treatment-program-otp-accreditation/#:~:text=Federal%20regulations%20define%20opioid%20treatment,effects%20incident%20to%20opiate%20addiction%E2%80%9D. (Accessed 13 June 2020).

Volkow, N. D. (2020). Collision of the COVID-19 and addiction epidemics. Ideas and Opinions: Annals of Internal Medicine.